← All trials
NCT05679895
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jun 25, 2025
- Completion date
- Jan 25, 2026
- First posted
- Jan 11, 2023
- Last posted
- Feb 14, 2023
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OneChain ImmunotherapeuticsLead sponsor
- University of BarcelonaCollaborator
- University of BarcelonaCollaborator
- BioClever 2005 S.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.